
Cell wall inhibitors - Pipeline Insight, 2024
Description
Cell wall inhibitors - Pipeline Insight, 2024
DelveInsight’s, “Cell wall inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Cell wall inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cell wall inhibitors: Overview
Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the β-lactams and glycopeptide antibiotics. They control Gram-negative and Gram-positive bacterial infection by inhibition of cell wall synthesis and have been used for many decades.
- β-Lactam antibiotics: They are a broad class of antibiotics that inhibit cell wall synthesis, consisting of all antibiotic agents that contain a β-lactam nucleus in their molecular structures. Some commonly used β-Lactam antibiotics include penicillins, ciclosporins, monobactams, and carbapenems. They are bactericidal and act by inhibiting the synthesis of peptidoglycan layers in the bacterial cell wall.
- Glycopeptide antibiotics: They are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Some important glycopeptide antibiotics include vancomycin, teicoplanin, telavancin, bleomycin, and ramoplanin. They inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cell wall inhibitors R&D. The therapies under development are focused on novel approaches for Cell wall inhibitors.
This segment of the Cell wall inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell wall inhibitors Emerging Drugs
- CONTEPO: Nabriva Therapeutics
The FDA has granted CONTEPO Qualified Infectious Disease Product (QIDP) and Fast Track designations for: Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI). It is currently in preregistration phase of development and is being developed by Nabriva Therapeutics.
- Tebipenem pivoxil: Spero Therapeutics
It is currently in phase III stage of development is being developed by Spero Therapeutics.
Further product details are provided in the report……..
Cell wall inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Cell wall inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Cell wall inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Cell wall inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cell wall inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell wall inhibitors drugs.
Cell wall inhibitors Report Insights
- Cell wall inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Cell wall inhibitors drugs?
- How many Cell wall inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Cell wall inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cell wall inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cell wall inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Recce Pharmaceuticals
- Spero Therapeutics
- Nabriva Therapeutics
- Karveel Pharmaceuticals
- Seachaid Pharmaceuticals
- RECCE-327
- RECCE-111
- Tebipenem pivoxil
- CONTEPO
- SNP021062
- SP1001
- SP-2078
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Cell wall inhibitors: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cell wall inhibitors– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Cell wall inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Cell wall inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Tebipenem pivoxil: Spero Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- RECCE-111: Recce Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cell wall inhibitors Key Companies
- Cell wall inhibitors Key Products
- Cell wall inhibitors- Unmet Needs
- Cell wall inhibitors- Market Drivers and Barriers
- Cell wall inhibitors- Future Perspectives and Conclusion
- Cell wall inhibitors Analyst Views
- Cell wall inhibitors Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.